CN110680803A - Selamectin ethosome preparation and preparation method and application thereof - Google Patents

Selamectin ethosome preparation and preparation method and application thereof Download PDF

Info

Publication number
CN110680803A
CN110680803A CN201910986012.9A CN201910986012A CN110680803A CN 110680803 A CN110680803 A CN 110680803A CN 201910986012 A CN201910986012 A CN 201910986012A CN 110680803 A CN110680803 A CN 110680803A
Authority
CN
China
Prior art keywords
parts
selamectin
preparation
ethosome
alcohol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201910986012.9A
Other languages
Chinese (zh)
Inventor
廖申权
孙铭飞
戚南山
吕敏娜
吴彩艳
李娟�
林栩慧
胡俊菁
蔡海明
于林增
肖文婉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Animal Health of Guangdong Academy of Agricultural Sciences
Original Assignee
Institute of Animal Health of Guangdong Academy of Agricultural Sciences
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Animal Health of Guangdong Academy of Agricultural Sciences filed Critical Institute of Animal Health of Guangdong Academy of Agricultural Sciences
Priority to CN201910986012.9A priority Critical patent/CN110680803A/en
Publication of CN110680803A publication Critical patent/CN110680803A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides

Abstract

The invention discloses a selamectin ethosome preparation, a preparation method and application thereof, wherein the parasite expelling preparation comprises the following components: selamectin, egg yolk lecithin, alcohol (including ethanol and propylene glycol), tween-80 and phosphate buffer. Compared with a selamectin transdermal agent, the invention greatly reduces the toxicity, and has the advantages of good skin permeability, biological slow release, longer action time, good stability and high safety. Animal experiments prove that the ethosome preparation has the effect of resisting in-vivo and in-vitro parasitic infection of dogs and cats.

Description

Selamectin ethosome preparation and preparation method and application thereof
Technical Field
The invention belongs to the field of insect control, and particularly relates to a selamectin ethosome preparation as well as a preparation method and application thereof.
Background
In recent years, with the rapid development of socioeconomic performance, the standard of living of people has been improved. Raising pets is increasingly favored by people. Parasitic diseases cause a series of problems for pets. The pet parasites are of various types, wherein the toxocara gondii is an important nematode parasitizing in dogs and cats, can cause the migration of animal internal organs and eye larvae, and is a zoonosis. The heartworm and lung failure and even death can be caused when the adult heartworm and lung are parasitized in the right ventricle and pulmonary artery of the dog. The heartworm transmission medium is a mosquito, a person is not a suitable host of the heartworm, but the person is bitten by the mosquito containing the larvae in the heartworm infection stage, and the infection can happen occasionally, which is shown as the formation of worm nodules by lung or subcutaneous tissue. Secondly, the infection rate of ectoparasites such as ticks, mites, fleas and lice of dogs and cats is still high and is distributed around the world, so that skin itch, depilation, red swelling, scabbing and the like of dogs and cats are caused, and the health of pets is seriously influenced. Brings certain influence to the health of pets and human beings, causes hidden health troubles,
the selamectin is a new generation of abamectin antiparasitic drug, the traditional transdermal agent is a traditional and main preparation form, and the slow-release, controlled-release and targeted drug delivery effects can be achieved by changing the selamectin preparation in order to improve the bioavailability of the drug.
The insect repellent preparation for pets mainly comprises 3 dosage forms: transdermal agents, oral agents and injections. When the composition is used for pets, the main preparation form is transdermal agent, and the parasite on the body surface of animals can be killed by simple operation. However, the drug effect of the selamectin is not long, and the penetration effect of the transdermal agent is not obvious. In view of the existing problems, the invention needs a medicament capable of effectively preventing or treating pet epizoonosis.
Disclosure of Invention
The invention aims at providing a selamectin ethosome preparation.
It is a further object of the present invention to provide a method for preparing the above-described ethosomes formulation.
It is yet another object of the present invention to provide a method for reducing parasites in animals.
It is a further object of the present invention to provide the use of the above-described ethosomes formulations.
The inventor finds that fipronil and methoprene are compounded in the existing scheme, but the effect of treating parasites is not obvious, the parasites cannot be completely killed, the drug action time is short, and a targeted, sustained-release and efficient transdermal drug delivery dosage form is lacked.
In order to achieve the purpose, the technical scheme adopted by the invention is as follows:
in one aspect of the invention, a selamectin ethosome preparation is provided, which comprises the following components: selamectin, yolk lecithin, alcohol Tween-80 and phosphate buffer solution; the alcohol is ethanol and propylene glycol.
Further, the composition comprises the following components in parts by weight: 8.0-12.0 parts of selamectin; 2.0-2.5 parts of egg yolk lecithin; 30.0 parts of alcohol; and 55.0-65.0 parts of phosphate buffer solution by weight of 800.5 parts of tween-water.
Further, the composition comprises the following components in parts by weight: 8.0-10.5 parts of selamectin; 2.0-2.3 parts of egg yolk lecithin; 30.0 parts of alcohol; tween-800.5 parts and 57.0-65.0 parts of phosphate buffer solution.
Further, the composition comprises the following components in parts by weight: 10.0 parts of selamectin; 2.0 parts of egg yolk lecithin; 32.0 parts of alcohol; tween-80, 0.5 parts and 55.5 parts phosphate buffer.
In another aspect of the invention, a method for preparing an imidacloprid and moxidectin diol liposome preparation is provided, which comprises the following steps:
(1) weighing selamectin, yolk lecithin and tween-80 according to any one of the above formulas, and stirring under sealed condition until the selamectin, the yolk lecithin and the tween-80 are dissolved;
(2) dropping phosphate buffer solution while stirring, and cooling to room temperature;
(3) performing ultrasonic treatment to obtain a nano ethosome preparation;
(4) filtering to obtain the selamectin ethosome preparation with nano granularity and uniform distribution.
Further, the stirring temperature in the step (1) is 29.5-30.5 ℃, and the stirring speed is 600-800 rpm; the dropping speed in the step (2) is 3-6 mL/min; the pH value of the phosphate buffer solution is 6.5-7.0; the stirring time is 20-30 min.
Further, in the step (3), the ultrasonic power is 100-120W, and the frequency is 45-50 kHz; carrying out ultrasonic treatment for 3-4 s at intervals of 3-4 s for 30-40 cycles; filtering by a 50-100 nm microporous polycarbonate membrane for 10-15 times.
It is yet another object of the present invention to provide a method for reducing parasites in animals. The method for reducing parasites in animals is: applying any one of the above glycol plastid preparations to dry skin of an animal; the smearing mode is selected from pouring or dipping; the skin is back and neck skin.
The invention also aims to provide the application of the dialcohol plastid preparation in preparing medicaments. The use of the above-mentioned glycol plastid preparation in the preparation of a medicament for the control of animal parasites; the animal is a dog or a cat; the skin is back and neck skin; the parasites can be reduced in number by applying the formulation of glycol plastids to dry skin of the animal.
Further, the parasites include ectoparasites and endoparasites; the endoparasite comprises a roundworm or heartworm; the ectoparasites include ticks, scabies, fleas or lice.
The invention has the beneficial effects that:
the invention takes the selamectin as the main effective component, combines with other substances to prepare an ethosome preparation, takes ethosome as a percutaneous administration form of the selamectin, avoids the first pass effect of the medicament, maintains constant blood concentration and pharmacological effect, thereby enhancing the treatment effect of the medicament, reducing adverse reaction and achieving the slow release effect. The ethosome preparation of the selamectin is beneficial to improving the transdermal depth and the epidermal and dermal drug retention of the selamectin, so that the drug can reach longer effective action time, the insect expelling effect of the preparation is improved, the action time of the preparation is prolonged, the insect expelling number can be effectively reduced, and the treatment effect is improved.
Detailed Description
In one aspect of the invention, a selamectin ethosome preparation is provided, which comprises the following components: selamectin, yolk lecithin, alcohol Tween-80 and phosphate buffer solution; the alcohol is ethanol and propylene glycol.
Preferably, the composition comprises the following components in parts by weight: 8.0-12.0 parts of selamectin; 2.0-2.5 parts of egg yolk lecithin; 30.0 parts of alcohol; and 55.0-65.0 parts of phosphate buffer solution by weight of 800.5 parts of tween-water.
Preferably, the composition comprises the following components in parts by weight: 8.0-10.5 parts of selamectin; 2.0-2.3 parts of egg yolk lecithin; 30.0 parts of alcohol; tween-800.5 parts and 57.0-65.0 parts of phosphate buffer solution.
Preferably, the composition comprises the following components in parts by weight: 10.0 parts of selamectin; 2.0 parts of egg yolk lecithin; 32.0 parts of alcohol; tween-80, 0.5 parts and 55.5 parts phosphate buffer.
In another aspect of the invention, a method for preparing an imidacloprid and moxidectin diol liposome preparation is provided, which comprises the following steps:
(1) weighing selamectin, yolk lecithin and tween-80 according to any one of the above formulas, and stirring under sealed condition until the selamectin, the yolk lecithin and the tween-80 are dissolved;
(2) dropping phosphate buffer solution while stirring, and cooling to room temperature;
(3) performing ultrasonic treatment to obtain a nano ethosome preparation;
(4) filtering to obtain the selamectin ethosome preparation with nano granularity and uniform distribution.
Preferably, the stirring temperature in the step (1) is 29.5-30.5 ℃, and the stirring speed is 600-800 rpm; the dropping speed in the step (2) is 3-6 mL/min; the pH value of the phosphate buffer solution is 6.5-7.0; the stirring time is 20-30 min.
Preferably, the ultrasonic power in the step (3) is 100-120W, and the frequency is 45-50 kHz; carrying out ultrasonic treatment for 3-4 s at intervals of 3-4 s for 30-40 cycles; filtering by a 50-100 nm microporous polycarbonate membrane for 10-15 times.
It is yet another object of the present invention to provide a method for reducing parasites in animals. The method for reducing parasites in animals is: applying any one of the above glycol plastid preparations to dry skin of an animal; the smearing mode is selected from pouring or dipping; the skin is back and neck skin.
The invention also aims to provide the application of the dialcohol plastid preparation in preparing medicaments. The use of the above-mentioned glycol plastid preparation in the preparation of a medicament for the control of animal parasites; the animal is a dog or a cat; the skin is back and neck skin; the parasites can be reduced in number by applying the formulation of glycol plastids to dry skin of the animal.
Further, the parasites include ectoparasites and endoparasites; the endoparasite comprises a roundworm or heartworm; the ectoparasites include ticks, scabies, fleas or lice.
The technical solution of the present invention is clearly and completely illustrated below with reference to the following examples, but is not limited thereto.
Example 1
The selamectin ethosome preparation comprises the following components in parts by weight: 8.0 parts of selamectin; 2.0 parts of egg yolk lecithin; 30.0 parts of alcohol (ethanol: propylene glycol ═ 6.5: 3.5); tween-80, 0.5 parts and phosphate buffer (pH 6.5). (taking a total of 100ml as an example)
A preparation method of a selamectin ethosome preparation comprises the following steps:
(1) weighing selamectin, yolk lecithin, alcohol (ethanol: propylene glycol ═ 6.5:3.5) and tween-80 according to the proportion, adding into a reaction tank, stirring at the temperature of 30 ℃ and the stirring speed of 700rpm, and stirring until the selamectin, the yolk lecithin, the alcohol and the tween-80 are dissolved;
(2) then adding phosphate buffer (pH 6.5) at a dropping rate of 1mL/min, stirring under sealed condition for 20min until complete dissolution, and cooling to room temperature;
(3) performing ultrasonic treatment for 3s at an ultrasonic power of 100W and an ultrasonic frequency of 45kHz at an interval of 3s for 30 cycles, and performing ultrasonic treatment by an ultrasonic pulverizer to obtain a nano ethosomes preparation;
(4) filtering with 100nm microporous polycarbonate membrane for 10 times to obtain nanometer eudragit ethosome preparation with uniform particle size distribution.
The selamectin ethosome preparation is characterized in that: the particle size is 46nm, the Zeta potential is-23.41 mV, the drug loading rate is 76.40 parts, the encapsulation rate is 97.05 parts, and the retention of the drug in the dermal layer of the epidermis is 27.11 mu g/cm2。
Example 2
The selamectin ethosome preparation comprises the following components in parts by weight: 10.0 parts of selamectin; 2.0 parts of egg yolk lecithin; 32.0 parts of alcohol (ethanol: propylene glycol ═ 6.5: 3.5); tween-80, 0.5 parts and phosphate buffer (pH 6.5). (taking a total of 100ml as an example)
A preparation method of a selamectin ethosome preparation comprises the following steps:
(1) weighing selamectin, yolk lecithin, alcohol (ethanol: propylene glycol ═ 6.5:3.5) and tween-80 according to the proportion, adding into a reaction tank, stirring at the temperature of 30 ℃ and the stirring speed of 700rpm, and stirring until the selamectin, the yolk lecithin, the alcohol and the tween-80 are dissolved;
(2) then adding phosphate buffer (pH 6.5) at a dropping rate of 1mL/min, stirring under sealed condition for 20min until complete dissolution, and cooling to room temperature;
(3) performing ultrasonic treatment for 3s at an ultrasonic power of 100W and an ultrasonic frequency of 45kHz at an interval of 3s for 30 cycles, and performing ultrasonic treatment by an ultrasonic pulverizer to obtain a nano ethosomes preparation;
(4) filtering with 100nm microporous polycarbonate membrane for 10 times to obtain nanometer eudragit ethosome preparation with uniform particle size distribution.
The selamectin ethosome preparation is characterized in that: the particle size is 44nm, the Zeta potential is-25.58 mV, the drug loading rate is 77.79 parts, the encapsulation rate is 98.01 parts, and the retention of the drug in the dermal layer of the epidermis is 28.35 mu g/cm2。
Example 3
The selamectin ethosome preparation comprises the following components in parts by weight: 12.0 parts of selamectin; 2.5 parts of egg yolk lecithin; 35.0 parts of alcohol (ethanol: propylene glycol ═ 6.5: 3.5); tween-80, 0.5 parts and phosphate buffer (pH 6.5). (taking a total of 100ml as an example)
A preparation method of a selamectin ethosome preparation comprises the following steps:
(1) weighing selamectin, yolk lecithin, alcohol (ethanol: propylene glycol ═ 6.5:3.5) and tween-80 according to the proportion, adding into a reaction tank, stirring at the temperature of 30 ℃ and the stirring speed of 700rpm, and stirring until the selamectin, the yolk lecithin, the alcohol and the tween-80 are dissolved;
(2) then adding phosphate buffer (pH 6.5) at a dropping rate of 1mL/min, stirring under sealed condition for 20min until complete dissolution, and cooling to room temperature;
(3) performing ultrasonic treatment for 3s at an ultrasonic power of 100W and an ultrasonic frequency of 45kHz at an interval of 3s for 30 cycles, and performing ultrasonic treatment by an ultrasonic pulverizer to obtain a nano ethosomes preparation;
(4) filtering with 100nm microporous polycarbonate membrane for 10 times to obtain nanometer eudragit ethosome preparation with uniform particle size distribution.
The selamectin ethosome preparation is characterized in that: the particle size is 41nm, the Zeta potential is-23.94 mV, the drug loading rate is 78.14 parts, the encapsulation rate is 98.97 parts, and the retention of the drug in the dermal layer of the epidermis is 27.40 mu g/cm2。
Example 4
The selamectin ethosome preparation comprises the following components in parts by weight: 11.0 parts of selamectin; 2.0 parts of egg yolk lecithin; 32.0 parts of alcohol (ethanol: propylene glycol ═ 6.5: 3.5); tween-80, 0.5 parts and 54.5 parts of phosphate buffer (pH 6.5). (taking a total of 100ml as an example)
A preparation method of a selamectin ethosome preparation comprises the following steps:
(1) weighing selamectin, yolk lecithin, alcohol (ethanol: propylene glycol ═ 6.5:3.5) and tween-80 according to the proportion, adding into a reaction tank, stirring at the temperature of 30 ℃ and the stirring speed of 700rpm, and stirring until the selamectin, the yolk lecithin, the alcohol and the tween-80 are dissolved;
(2) then adding phosphate buffer (pH 6.5) at a dropping rate of 1mL/min, stirring under sealed condition for 20min until complete dissolution, and cooling to room temperature;
(3) performing ultrasonic treatment for 4s at an ultrasonic power of 100W and an ultrasonic frequency of 45kHz at an interval of 4s for 40 cycles, and performing ultrasonic treatment by an ultrasonic pulverizer to obtain a nano ethosomes preparation;
(4) filtering with 100nm microporous polycarbonate membrane for 15 times to obtain nanometer eudragit ethosome preparation with uniform particle size distribution.
Example 5
The selamectin ethosome preparation comprises the following components in parts by weight: 10.0 parts of selamectin; 2.0 parts of egg yolk lecithin; 32.0 parts of alcohol (ethanol: propylene glycol ═ 6.5: 3.5); tween-80, 0.5 parts and 55.5 parts of phosphate buffer (pH 6.5). (taking a total of 100ml as an example)
A preparation method of a selamectin ethosome preparation comprises the following steps:
(1) weighing selamectin, yolk lecithin, alcohol (ethanol: propylene glycol ═ 6.5:3.5) and tween-80 according to the proportion, adding into a reaction tank, stirring at the temperature of 30 ℃ and the stirring speed of 700rpm, and stirring until the selamectin, the yolk lecithin, the alcohol and the tween-80 are dissolved;
(2) then adding phosphate buffer (pH 6.5) at a dropping rate of 1mL/min, stirring under sealed condition for 20min until complete dissolution, and cooling to room temperature;
(3) performing ultrasonic treatment for 3s at an ultrasonic power of 100W and an ultrasonic frequency of 45kHz at an interval of 3s for 30 cycles, and performing ultrasonic treatment by an ultrasonic pulverizer to obtain a nano ethosomes preparation;
(4) filtering with 100nm microporous polycarbonate membrane for 12 times to obtain nanometer eudragit ethosome preparation with uniform particle size distribution.
Comparative example 1
A selamectin transdermal agent comprising: 12.0 parts of selamectin, 5 parts of propylene glycol and 83 parts of ethanol.
The antiparasitic effect of the selamectin ethosome is illustrated below in connection with specific experiments.
Experimental materials:
control drugs: a selamectin transdermal agent.
Selamectin ethosome: the formulations are examples.
Experimental animals: 50 affected dogs veterinarily diagnosed with ectoparasites were provided by a canine farm.
50 diseased cats with ectoparasites diagnosed by a veterinarian were provided by the cat farm.
The experimental method comprises the following steps:
grouping: the 50 affected dogs were randomly divided into 7 groups, which were experimental group 1-5, drug control group and blank control group. The 50 diseased cats were randomly divided into 7 groups, which were experimental 8-12, drug control and blank control groups, respectively.
And (3) treatment: groups 1-6, administered at a dose of 0.1ml per 1Kg body weight, dropped between scapulae on the back of a dog, administered 1 time, and the healing condition was observed.
The control dogs were not dosed and observed for onset of disease.
Groups 8-13, administered 0.1ml per 1Kg body weight, dropped between scapulae on back of cat, administered 1 time, and the cure condition was observed. The cats in the control group were not treated with the drug and the onset of the disease was observed. The test lasted 1 month. The experimental groups are shown in Table 1.
TABLE 1 groups of tests
Scraping skin tissue at the junction of the diseased part and the healthy skin on days 1, 2, 7, 14, 21, 28, 35, 42, 49, 56 and 63 after administration, placing the skin tissue in a culture dish, and inspecting the conditions of worms, mites, fleas, lice and ova by a humidifying method;
collecting fecal samples on days 1, 2, 7, 14, 21, 28, 35, 42, 49, 56 and 63 after administration, and detecting ascarid and heartworm ovum condition.
The reduction rate was calculated according to the following formula. Evaluation of results, cure: clinical symptoms disappear, and the insect reduction rate is more than 80 parts; the method has the following advantages: the disease condition is obviously improved, and 80 parts of the pesticide composition is more than or equal to 60 parts of the pest reduction rate; and (4) invalidation: the disease condition is not obviously improved or aggravated, and the insect reduction rate is less than 60 parts.
Reduction rate (in parts) is (average number of adults detected in control group-average number of adults detected in experimental group)/(average number of adults detected in control group)
The experimental results are as follows:
the relevant clinical symptoms of the experimental animals were observed and recorded daily. 2 days after the administration, the symptoms of ectoparasite infection were reduced in groups 1 to 6 and 8 to 13 to which the preparations of examples were added, and the crust portion fell off. After 7 days of administration, the symptoms of ectoparasite infections completely disappeared from groups 1-6, and 8-13, and the presence of worms, fleas and eggs was not detected by microscopic examination. There was no improvement in symptoms in control group 7 and control group 14. The specific experimental results are shown in table 2.
TABLE 2 clinical efficacy of the groups on ectoparasites of the experimental animals
Figure BDA0002236708880000081
In summary, the alcoholic formulations of selamectin according to the invention can be used for controlling/combating (i.e. significantly reducing or even eliminating the number of parasites) ectoparasites. The parasites include ectoparasites and endoparasites; the endoparasites include roundworms, heartworms; the ectoparasites include ticks, scabies, fleas or lice.
The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, and simplifications which do not depart from the spirit and principle of the present invention should be construed as equivalents thereof, and all such changes, modifications, substitutions, combinations, and simplifications are intended to be included in the scope of the present invention.

Claims (10)

1. An ethosome preparation, which is characterized by comprising selamectin, yolk lecithin, alcohol, Tween-80 and phosphate buffer; the alcohol is ethanol and propylene glycol.
2. The ethosome formulation according to claim 1, characterized by comprising the following ingredients in parts by weight: 8.0-12.0 parts of selamectin; 2.0-2.5 parts of egg yolk lecithin; 30.0 parts of alcohol; tween-800.5 parts and 55.0-65.0 parts of phosphate buffer solution.
3. The ethosome formulation according to claim 2, characterized by comprising the following ingredients in parts by weight: 8.0-10.5 parts of selamectin; 2.0-2.3 parts of egg yolk lecithin; 30.0 parts of alcohol; tween-800.5 parts and 57.0-65.0 parts of phosphate buffer solution.
4. The ethosome formulation according to claim 3, characterized by comprising the following ingredients in parts by weight: 10.0 parts of selamectin; 2.0 parts of egg yolk lecithin; 32.0 parts of alcohol; tween-80, 0.5 parts and 55.5 parts of phosphate buffer.
5. The method for preparing a liposome preparation according to any one of claims 1 to 4, comprising the steps of:
(1) weighing selamectin, egg yolk lecithin, alcohol and tween-80 according to the formula of any one of claims 1 to 4, and stirring in a closed state until the selamectin, the egg yolk lecithin, the alcohol and the tween-80 are dissolved;
(2) dropping phosphate buffer solution while stirring, and cooling to room temperature;
(3) obtaining a nanometer ethosome by ultrasonic;
(4) filtering to obtain the selamectin ethosome.
6. The preparation method according to claim 5, wherein the stirring temperature in the step (1) is 29.5 to 30.5 ℃, and the stirring speed is 600 to 800 rpm; the dropping speed in the step (2) is 3-6 mL/min; the pH value of the phosphate buffer solution is 6.5-7.0; the stirring time is 20-30 min.
7. The preparation method according to claim 5, wherein the ultrasonic power in the step (3) is 100-120W, and the frequency is 45-50 kHz; carrying out ultrasonic treatment for 3-4 s at intervals of 3-4 s for 30-40 cycles; filtering by a 50-100 nm microporous polycarbonate membrane for 10-15 times.
8. A method for reducing parasites on animals, comprising applying an ethosome formulation according to any one of claims 1 to 4 to the dry skin of an animal; the smearing mode is selected from pouring or dipping; the skin is back and neck skin.
9. Use of an ethosome formulation according to any one of claims 1 to 4 for the preparation of a medicament for the control of animal parasites; the animal is a dog and/or a cat; the skin is back and neck skin; the parasites can be reduced in number by applying the formulation of glycol plastids to dry skin of the animal.
10. The use according to claim 9, wherein the parasites comprise ectoparasites and endoparasites; the endoparasite comprises a roundworm or heartworm; the ectoparasites include ticks, scabies, fleas or lice.
CN201910986012.9A 2019-10-17 2019-10-17 Selamectin ethosome preparation and preparation method and application thereof Pending CN110680803A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910986012.9A CN110680803A (en) 2019-10-17 2019-10-17 Selamectin ethosome preparation and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910986012.9A CN110680803A (en) 2019-10-17 2019-10-17 Selamectin ethosome preparation and preparation method and application thereof

Publications (1)

Publication Number Publication Date
CN110680803A true CN110680803A (en) 2020-01-14

Family

ID=69113046

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910986012.9A Pending CN110680803A (en) 2019-10-17 2019-10-17 Selamectin ethosome preparation and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN110680803A (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008052263A1 (en) * 2006-11-01 2008-05-08 Veterinary Encapsulation Biosciences Pty Ltd Delivery system for remote treatment of an animal
CN101273971A (en) * 2008-05-09 2008-10-01 绍兴文理学院 Ethosomes preparation of antimycotics pharmaceutical and method for preparing the same
CN102949340A (en) * 2011-08-24 2013-03-06 中国农业科学院兰州畜牧与兽药研究所 Sarah rhzomorph nano emulsion medicine composition and preparation method thereof
WO2015123750A1 (en) * 2014-02-20 2015-08-27 Cura Health Inc. Transdermal composition for treating pain

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008052263A1 (en) * 2006-11-01 2008-05-08 Veterinary Encapsulation Biosciences Pty Ltd Delivery system for remote treatment of an animal
CN101273971A (en) * 2008-05-09 2008-10-01 绍兴文理学院 Ethosomes preparation of antimycotics pharmaceutical and method for preparing the same
CN102949340A (en) * 2011-08-24 2013-03-06 中国农业科学院兰州畜牧与兽药研究所 Sarah rhzomorph nano emulsion medicine composition and preparation method thereof
WO2015123750A1 (en) * 2014-02-20 2015-08-27 Cura Health Inc. Transdermal composition for treating pain

Similar Documents

Publication Publication Date Title
Boden Black's veterinary dictionary
CN105853454A (en) Broad-spectrum antiparasitic drug nano-emulsion and preparation method thereof
Boden et al. Black's veterinary dictionary
EP3319599B1 (en) Kit-of-parts comirising a combination of dinotefuran/permethrin/pyriproxyfen for topical use and oral milbemycin oxime for controlling the spread of dirofilariosis
CN111514157A (en) Application of composition in preparation of veterinary anti-parasitic drug, veterinary anti-parasitic transdermal solution and preparation method thereof
CA2806133C (en) Compositions for controlling heartworm infestation
CN110664806B (en) Fipronil and methoprene dihydric alcohol plastid and preparation method and application thereof
US20160250244A1 (en) Compositions for treating heartworm infestation
CN110772509A (en) Imidacloprid and moxidectin diatomic alcohol plastid and preparation method and application thereof
CN114259464B (en) Compound moxidectin external drop
CN110680803A (en) Selamectin ethosome preparation and preparation method and application thereof
JP2008535901A (en) Treatment of human and animal parasitic infections
JP2003514834A (en) Combination of N-phenyl-N'-benzoylurea derivative and nectin compound for controlling parasites
CN110721152B (en) Sustained-release composition for treating animal skin parasite and fungus infection
CN107157995A (en) A kind of compound imidacloprid transdermal composition preparation of pet broad-spectrum anti-parasite
RU2709535C1 (en) Method for preventing and treating parasitic diseases of farm animals and birds
Boden et al. Black's student veterinary dictionary
Barron Appendix II Formulary for Common Wildlife Species
RU2251421C2 (en) Antiparasitic preparation for needle-free injection
RU2519085C1 (en) Antiparasitic agent for farm animals
CN112294831B (en) Transdermal drop for expelling parasites on animals and preparation method thereof
CN103330679B (en) Film coating agent for treating pigeon ectozoa and preparation method thereof
Knotek Therapeutics and medication
RU2140737C1 (en) Agent for prophylaxis and treatment of animals with parasitic sicknesses
CN114681479A (en) Insect repellent and using method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20200114